15 May 2024 in Clinical Pharmacology & Therapeutics
27 February 2025 in Clinical Cancer Research
Patient-reported outcomes (PRO) play a crucial role as clinical endpoint in oncology trials. Traditional statistical methods, such as hypothesis testing, have been commonly used by pharmaceutical industry and regulators to evaluate treatment efficacy on PRO endpoints. However, the analysis of PRO data remains challenging because of high variability and missing data issues. In this study, we will present examples in which inappropriate statistical analyses of PRO data can confound treatment efficacy analyses. To overcome these challenges, we propose the application of individual participant data and population models. Population models have been extensively used in pharmacokinetics and pharmacodynamics analyses and are well accepted by regulators. However, their potential in PRO data analyses, particularly in the field of oncology, remains largely untapped. This perspective article aims to highlight the value of population modeling approaches in PRO data analyses for oncology clinicians and researchers. Population models integrate individual participant data and can effectively handle the substantial variability in PRO measurements by incorporating covariates, between-subject variability, and accounting for measurement noise. By leveraging information from the population, this approach also provides accurate estimations for participants with missing data or sparse sampling. Moreover, these models could be applied to predict long-term PRO dynamics. If used appropriately, population modeling approaches could revolutionize the analysis of PRO data in oncology drug development, enabling a more comprehensive understanding of the impact of treatment on patients’ lives. Our aim is to encourage stakeholders to consider population modeling as a standard and effective tool to enhance decision-making and ultimately improve patient care.
14 March 2025 in Clinical Pharmacology & Therapeutics
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience. To overcome these hurdles, Model‐Informed Drug Development (MIDD) emerges as a valuable tool that can be applied to mRNA‐LNP therapeutics, facilitating the evaluation of their safety and efficacy through the integration of data from all stages into appropriate modeling and simulation techniques. In this review, we provide an overview of current MIDD applications in mRNA‐LNP therapeutics clinical development using in vivo data. A variety of modeling methods are reviewed, including quantitative system pharmacology (QSP), physiologically based pharmacokinetics (PBPK), mechanistic pharmacokinetics/pharmacodynamics (PK/PD), population PK/PD, and model‐based meta‐analysis (MBMA). Additionally, we compare the differences between mRNA‐based therapeutics, small interfering RNA, and adeno‐associated virus‐based gene therapies in terms of their clinical pharmacology, and discuss the potential for mutual sharing of MIDD knowledge between these therapeutics. Furthermore, we highlight the promising future opportunities for applying MIDD approaches in the development of mRNA‐LNP drugs. By emphasizing the importance of applying MIDD knowledge throughout mRNA‐LNP therapeutics development, this review aims to encourage stakeholders to recognize the value of MIDD and its potential to enhance the safety and efficacy evaluation of mRNA‐LNP therapeutics.
24 April 2025 in Clinical Cancer Research
Purpose: Despite their potential, patient-reported outcomes (PRO) are often underutilized in clinical decision-making, especially when improvements in PRO do not align with clinical outcomes. This misalignment may result from insufficient analytic methods that overlook the temporal dynamics and substantial variability of PRO data. To address these gaps, we developed a novel approach to investigate the prognostic value of longitudinal PRO dynamics in non–small cell lung cancer (NSCLC) using Lung Cancer Symptom Scale (LCSS) data. Experimental Design: Longitudinal patient-reported LCSS data from 481 participants with NSCLC in the placebo arm of a phase III trial were analyzed. A population modeling approach was applied to describe PRO progression trajectories while accounting for substantial variability in the data. Associations between PRO model parameters and survival outcomes were assessed using Cox proportional hazards models. Model-informed PRO parameters were used to predict survival via machine learning. Results: A PRO progression model described LCSS dynamics and predicted a median time to symptom progression of 229 days [95% confidence interval (CI), 15 –583]. Faster PRO progression rates were significantly associated with poorer survival (HR, 1.13; 95% CI, 1.076–1.18), while greater improved PRO effects by placebo/prior treatment correlated with improved survival (HR, 0.93; 95% CI, 0.883–0.99). A machine learning model using PRO parameters achieved an AUC ROC of 0.78, demonstrating their potential to predict overall survival. Conclusions: This study demonstrates that longitudinal PRO data can provide prognostic insights into survival in NSCLC. The findings support the use of PRO dynamics to improve clinical decision-making and optimize patient-centered treatment strategies.
30 September 2025 in CPT: Pharmacometrics & Systems Pharmacology
Pembrolizumab is an immune checkpoint inhibitor that has been approved for more than 20 different indications and has shown great survival benefits in various types of cancer. However, the reported benefits of pembrolizumab in patients' quality of life (QoL) have been inconsistent across different studies and different types of cancer. As oncology drug development increasingly emphasizes patient‐centered care, patient‐reported outcomes (PROs), particularly patient‐reported QoL, are recognized as important clinical endpoints. To characterize the effects of pembrolizumab on patient‐reported QoL, we conducted a model‐based meta‐analysis (MBMA) of published clinical trials evaluating pembrolizumab across different types of cancer. The longitudinal EORTC QLQ‐C30 GHS/QOL data were extracted in our analysis as QoL scores. A population model was developed to characterize the longitudinal QoL trajectories and quantify both treatment toxicity and efficacy. Out of more than 300 screened studies, only 20 reported longitudinal EORTC QLQ‐C30 QoL data. Among these, 8 studies reported no between‐group differences in QoL outcomes between pembrolizumab and control arms. However, our modeling revealed that pembrolizumab was associated with greater toxicity but improved long‐term QoL. Notably, our approach identified treatment effects on QoL that were not detected by traditional statistical analyses in the original publications. In summary, our study demonstrates that MBMA combined with population modeling enables more accurate evaluation of longitudinal PROs data, overcoming the limitations of conventional methods. This approach offers a robust framework for integrating patient‐centered outcomes into oncology drug development and supports the broader use of PROs data in regulatory and clinical decision‐making.
4 November 2025 in CPT: Pharmacometrics & Systems Pharmacology
Artificial intelligence (AI) is increasingly being explored as a tool to support pharmacometric modeling, particularly in addressing the coding challenges associated with NONMEM. In this study, we evaluated the ability of seven Large Language Models (LLMs) to generate NONMEM codes across 13 pharmacometrics tasks, including a range of population pharmacokinetic (PK) and pharmacodynamic (PD) models. We further developed a standardized scoring rubric to assess code accuracy and created an optimized prompt to improve LLM performance. Our results showed that the OpenAI o1 and gpt‐4.1 models achieved the best performance, both generating codes with great accuracy for all tasks when using our optimized prompt. Overall, LLMs performed well in writing basic NONMEM model structures, providing a useful foundation for pharmacometrics model coding. However, user review and refinement remain essential, especially for complex models with special dataset alignment or advanced coding techniques. We also discussed the applications of AI in pharmacometrics education, particularly strategies to prevent overreliance on AI for coding. This work provides a benchmark for current LLMs' performance in NONMEM coding and introduces a practical prompt that can facilitate more accurate and efficient use of AI in pharmacometrics research and education.